The CD10+GPR77+ CAF subset was linked to chemoresistance and poor prognosis in BC and lung cancer patients and a neutralizing anti-GPR77 antibody abolished tumor formation in PDX models, which indicated CAFs targeting as a therapeutic strategy that is able to affect the BCSCs compartment [136]. This evidence concerns the gene MME and breast cancer.